CA1148860A - Dose sous forme de capsule de gelatine, renfermant du triamterene - Google Patents

Dose sous forme de capsule de gelatine, renfermant du triamterene

Info

Publication number: CA1148860A
Authority: CA; Canada
Prior art keywords: gelatin capsule; triamterene; surfactant; carbonate; present
Prior art date: 1980-11-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000364963A

Other languages

English (en)

Inventor

Louis J. Ravin

Elisabeth S. Rattie

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

GlaxoSmithKline Inc

Original Assignee

Smith Kline and French Canada Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-11-19

Filing date

1980-11-19

Publication date

1983-06-28

1980-11-19 Application filed by Smith Kline and French Canada Ltd filed Critical Smith Kline and French Canada Ltd

1980-11-19 Priority to CA000364963A priority Critical patent/CA1148860A/fr

1983-06-28 Application granted granted Critical

1983-06-28 Publication of CA1148860A publication Critical patent/CA1148860A/fr

Status Expired legal-status Critical Current

Links

FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 title claims abstract description 26
229960001288 triamterene Drugs 0.000 title claims abstract description 25
239000007903 gelatin capsule Substances 0.000 title claims abstract description 18
239000004094 surface-active agent Substances 0.000 claims abstract description 14
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims abstract description 6
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims abstract description 5
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 12
229910000019 calcium carbonate Inorganic materials 0.000 claims description 6
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 4
229960002003 hydrochlorothiazide Drugs 0.000 claims description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
231100000252 nontoxic Toxicity 0.000 claims description 3
230000003000 nontoxic effect Effects 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
229910052783 alkali metal Inorganic materials 0.000 claims 2
150000001340 alkali metals Chemical class 0.000 claims 2
229910052791 calcium Inorganic materials 0.000 claims 2
229960005069 calcium Drugs 0.000 claims 2
235000001465 calcium Nutrition 0.000 claims 2
239000011575 calcium Substances 0.000 claims 2
150000005323 carbonate salts Chemical class 0.000 claims 2
238000004090 dissolution Methods 0.000 abstract description 10
239000003085 diluting agent Substances 0.000 abstract description 7
239000002552 dosage form Substances 0.000 abstract description 5
239000004480 active ingredient Substances 0.000 abstract description 2
239000002775 capsule Substances 0.000 description 8
239000004615 ingredient Substances 0.000 description 8
239000003814 drug Substances 0.000 description 7
108010010803 Gelatin Proteins 0.000 description 4
229940014259 gelatin Drugs 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000006185 dispersion Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
239000008187 granular material Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 2
229940097420 Diuretic Drugs 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
239000002934 diuretic Substances 0.000 description 2
230000001882 diuretic effect Effects 0.000 description 2
230000036571 hydration Effects 0.000 description 2
238000006703 hydration reaction Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000000034 method Methods 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
-1 thiazide compound Chemical class 0.000 description 2
239000003451 thiazide diuretic agent Substances 0.000 description 2
CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
XZRKEDHJXXLVSK-UHFFFAOYSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;6-phenylpteridine-2,4,7-triamine Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 XZRKEDHJXXLVSK-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229940121792 Thiazide diuretic Drugs 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
229960003515 bendroflumethiazide Drugs 0.000 description 1
HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 1
229960001541 benzthiazide Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
229960002155 chlorothiazide Drugs 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
RGUQWGXAYZNLMI-UHFFFAOYSA-N flumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O RGUQWGXAYZNLMI-UHFFFAOYSA-N 0.000 description 1
229960003028 flumethiazide Drugs 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 1
229960003313 hydroflumethiazide Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229940097271 other diuretics in atc Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
239000013589 supplement Substances 0.000 description 1
229940083085 thiazide derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
229960004813 trichlormethiazide Drugs 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CA000364963A 1980-11-19 1980-11-19 Dose sous forme de capsule de gelatine, renfermant du triamterene Expired CA1148860A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000364963A CA1148860A (fr)	1980-11-19	1980-11-19	Dose sous forme de capsule de gelatine, renfermant du triamterene

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000364963A CA1148860A (fr)	1980-11-19	1980-11-19	Dose sous forme de capsule de gelatine, renfermant du triamterene

Publications (1)

Publication Number	Publication Date
CA1148860A true CA1148860A (fr)	1983-06-28

Family

ID=4118490

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000364963A Expired CA1148860A (fr)	1980-11-19	1980-11-19	Dose sous forme de capsule de gelatine, renfermant du triamterene

Country Status (1)

Country	Link
CA (1)	CA1148860A (fr)

1980
- 1980-11-19 CA CA000364963A patent/CA1148860A/fr not_active Expired

Legal Events

Date	Code	Title	Description
2000-06-28	MKEX	Expiry

Publication	Publication Date	Title
US4255413A (en)	1981-03-10	Gelatin capsule dosage unit containing triamterene
US4681765A (en)	1987-07-21	Rapid releasing triamterene containing gelatin capsule dosage forms for once daily antihypertensive use
EP1275391B1 (fr)	2011-03-30	Composition pharmaceutique contenant de l'irbesartan et un diurétique
CA2321523C (fr)	2008-10-07	Procede utilisant des super-desintegrants dans la preparation de capsules ou de comprimes d'efavirenz a dissolution rapide
CA1295247C (fr)	1992-02-04	Capsule a liberation lente
CA1275933C (fr)	1990-11-06	Compose therapeutique contenant de l'ibuprofen
EP0250023B1 (fr)	1991-08-14	Forme de dosage de la nitrofurantoine
AU712464B2 (en)	1999-11-04	Improvements in or relating to organic compositions
EP1100470B1 (fr)	2003-03-19	Compositions analgesiques a dissolution rapide contenant de l'ibuprofene
JPH05112445A (ja)	1993-05-07	作用開始を速くし潜在特性を増加させる移送システム
CA2000763C (fr)	2000-11-14	Produit dispersant
US3865935A (en)	1975-02-11	Tableting of erythromycin base
CA2009326C (fr)	1998-01-27	Solution pour granulation aqueuse et methode pour granulation de tablettes
US5322698A (en)	1994-06-21	Process for the preparation of a tablet or dragee composition containing a heat-, light- and moisture-sensitive active ingredient having monoclinic crystal structure
EP1429748B1 (fr)	2005-07-20	Compositions solides comprenant du ramipril
CA2050970C (fr)	2002-11-19	Compositions pharmaceutiques contenant des derives du furanne
SU1009467A1 (ru)	1983-04-07	Средство дл растворени мочевых конкрементов
CA1148860A (fr)	1983-06-28	Dose sous forme de capsule de gelatine, renfermant du triamterene
WO2023001880A1 (fr)	2023-01-26	Comprimé bicouche comprenant du telmisartan et de l'indapamide
IE50400B1 (en)	1986-04-16	Gelatin capsule dosage unit containing triamterene
US4536511A (en)	1985-08-20	Medicaments containing muzolimine, their use and processes for their production
FI82377C (fi)	1991-03-11	Foerfarande foer framstaellning av ett med baser bildat piroxicamsalt utfaellt pao en farmaceutiskt godtagbar baerare.
JPH0141607B2 (fr)	1989-09-06
JP4719899B2 (ja)	2011-07-06	口腔内速崩壊性錠剤
CA1209046A (fr)	1986-08-05	Composes diuretiques/antihypertenseurs et methode de preparation